NEW YORK, July 26, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company
developing innovative medicines and other products for targeting and treating cancer, announced today that it will host a
conference call and webcast to review the second quarter ended June 30, 2017 financial results on Wednesday, August 9, 2017, at
8:30 a.m. ET.
To participate, please dial (877) 250-8889 (domestic) or (720) 545-0001 (international) and reference conference
ID 59855960. A live webcast will be available in the Media Center of the Progenics website, www.progenics.com, and a replay will be available for two weeks.
About Progenics
Progenics Pharmaceuticals, Inc. develops innovative medicines and other technologies to target and treat cancer.
The Company's pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA® and 1095), 2)
PSMA-targeted imaging agents for prostate cancer (1404 and PyLTM), and 3) imaging analysis tools. Progenics' first
commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant
Pharmaceuticals International, Inc.
This press release may contain projections and other "forward-looking statements" regarding future events.
Statements contained in this communication that refer to Progenics' estimated or anticipated future results or other non-historical
facts are forward-looking statements that reflect Progenics' current perspective of existing trends and information as of the date
of this communication. Forward looking statements generally will be accompanied by words such as "anticipate," "believe," "plan,"
"could," "should," "estimate," "expect," "forecast," "outlook," "guidance," "intend," "may," "might," "will," "possible,"
"potential," "predict," "project," or other similar words, phrases or expressions. Such statements are predictions only, and are
subject to risks and uncertainties that could cause actual events or results to differ materially. More information concerning
Progenics and such risks and uncertainties is available on our website, and in our press releases and reports we file with the U.S.
Securities and Exchange Commission. Progenics is providing the information in this press release only as of its date and, except as
expressly required by law, Progenics disclaims any intent or obligation to update or revise any forward-looking statements, whether
as a result of new information, future events or circumstances or otherwise.
Additional information concerning Progenics and its business may be available in press releases or other
public announcements and public filings made after this release. For more information, please visit www.progenics.com. Please follow us on LinkedIn®. Information on or accessed
through our website or social media sites is not included in Progenics’ SEC filings.
(PGNX-F)
Contact: Melissa Downs Investor Relations (646) 975-2533 mdowns@progenics.com
